Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2013

01-06-2013 | Review

Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus

Author: Michael Bergman

Published in: Endocrine | Issue 3/2013

Login to get access

Abstract

Type 2 diabetes and other non-communicable diseases (NCD) are a growing public health challenge globally. An estimated 285 million people, corresponding to 6.4 % of the world’s adult population has diabetes. This is expected to reach 552 million by 2030, 7.8 % of the adult population, with the African region expected to experience the greatest increase. A much larger segment of the world’s population, approximating 79 million individuals in the US alone, has prediabetes. Multiple factors including genetic predisposition, insulin resistance, increased insulin secretory demand, glucotoxicity, lipotoxicity, impaired incretin release/action, amylin accumulation, and decreased β-cell mass play a causative role in the progressive β-cell dysfunction characteristic of prediabetes. Interventions preventing progression to type 2 diabetes should therefore delay or prevent β-cell failure. This article will first review the principal pathophysiological mechanisms underlying prediabetes and subsequently address treatment considerations based on these in the prevention of type 2 diabetes. In view of long-standing safety data with demonstrated efficacy and cost-effectiveness in the prevention of type 2 diabetes in high-risk individuals, metformin should be considered as initial therapy for those unable to comply with or lifestyle modification or where the latter has been ineffective in decreasing progression to type 2 diabetes.
Literature
1.
IDF, Diabetes Atlas Fourth Edition. International Diabetes Federation (Brussels, Belgium, 2009)
2.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20(7), 1183–1197 (1997)
3.
The Expert Committee on the diagnosis and classification of diabetes mellitus, Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26(11), 3160–3167 (2003)CrossRef
4.
American Diabetes Association, Standards of medical care in diabetes-2012. Diabetes Care 35(1), S11–S63 (2012)CrossRef
5.
The International Expert Committee, International expert committee report on the role of the A1c assay in the diagnosis of diabetes. Diabetes Care 32(7), 1327–1334 (2009)CrossRef
6.
WHO, Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. diabetes res. Clin. Pract. 93(3), 299–309 (2011)
7.
8.
R.A. DeFronzo, M.A. Abdul-Ghani, Preservation of β-cell function: the key to diabetes prevention. J. Clin. Endocrinol. Metab. 96(8), 2354–2366 (2011)PubMedCrossRef
9.
J. Shaw, R.A. Sicree, P.Z. Zimmet, Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract. 87(1), 4–14 (2010)PubMedCrossRef
10.
11.
I. Hopper, B. Billah, M. Skiba, H. Krum, Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomized controlled clinical trials. Eur. J. Cardiovasc. Prev. Rehabil. 18(6), 813–823 (2011)PubMed
12.
L. Perreault, Q. Pan, K.J. Mather, K.E. Watson, R.F. Hammam, S.E. Kahn, For the diabetes prevention program research group. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the diabetes prevention program outcomes study, Lancet published online June 9, (2012). (doi:10.​1016/​S0140-6736(12)60525-X
13.
A. Tirosh, I. Shai, D. Tekes-Manova, E. Israeli, D. Pereg, T. Shochat, I. Kochba, A. Rudich, For the Israeli diabetes research group, normal fasting plasma glucose levels and type 2 diabetes in young men. N. Engl. J. Med. 353(10), 1454–1462 (2005)PubMedCrossRef
14.
M. Bergman, Inadequacies of absolute threshold levels for diagnosing prediabetes. Diabetes Metab. Res. Rev. 26(1), 5–6 (2010)CrossRef
15.
E. Ferrannini, M. Massari, M. Nannipieri, A. Natali, R.L. Ridaura, C. Gonzales-Villalpando, Plasma glucose levels as predictors of diabetes: the Mexico city diabetes study. Diabetologia 52(5), 818–824 (2009)PubMedCrossRef
16.
Y. Heianza, Y. Arase, K. Fujihara, H. Tsuji, K. Saito, S.D. Hsieh, S. Kodama, H. Shimano, N. Yamada, S. Hara, H. Sone, Screening for pre-diabetes to predict future diabetes using various cut-off points for HbA1c and impaired fasting glucose the Toranomon hospital health management center study 4 (TOPCS 4). Diabetes Med. 29, e279–e285 (2012)CrossRef
17.
M.J. Picon, M. Murri, A. Muñoz, J.C. Fernandez-Garcia, R. Gomez-Huelgas, F.J. Tinahones, Hemoglobin A1c versus oral glucose tolerance test in postpartum diabetes screening. Diabetes Care 35(8), 1648–1653 (2012)PubMedCrossRef
18.
C. Weyer, C. Bogardus, D.M. Mott, R.E. Pratley, The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis if type 2 diabetes mellitus. J. Clin. Invest. 104(6), 787–794 (1999)PubMedCrossRef
19.
G.C. Weir, S. Bonner-Weir, Five stages of evolving β-cell dysfunction during progression to diabetes, Diabetes 53(12, suppl 3), S16–S21 (2004)PubMedCrossRef
20.
A. Vasudevan, A.J. Garber, Postprandial Hyperglycemia, in Contemporary Endocrinology: Type 2 Diabetes Mellitus : An Evidence-Based Approach to practical Management, ed. by M.N. Feinglos, M.A. Bethel (Humana Press, Totowa, 2008), pp. 97–113
21.
C.H. Courtney, J.M. Olefsky, Insulin Resistance, in Mechanisms of Insulin Action, ed. by A.R. Saltiel, J.E. Pessin (Landes Bioscience and Springer Science + Business Media, New York, 2007), pp. 185–209CrossRef
22.
D.M. Muoio, T.R. Koves, J. An, C. Newgard, Metabolic Mechanisms of Muscle Insulin Resistance, in Contemporary Endocrinology: Type 2 Diabetes Mellitus : An Evidence-Based Approach to Practical Management, ed. by M.N. Feinglos, M.A. Bethel (Humana Press, Totowa, 2008), pp. 97–113
23.
R.N. Bergman, Banting Lecture 2006. Orchestration of glucose homeostasis, from a small acorn to the California Oak. Diabetes 56(6), 1489–1501 (2007)PubMedCrossRef
24.
M.A. Abdul-Ghani, M.P. Stern, V. Lyssenko, T. Tuomi, L. Groop, R.A. DeFronzo, Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. Diabetes Care 33(3), 557–561 (2010)PubMedCrossRef
25.
D.A. Lang, D.R. Matthews, M. Burnett, R.C. Turner, Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes 30(5), 435–439 (1981)PubMedCrossRef
26.
S. O’Rahilly, R.C. Turner, D.R. Matthews, Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N. Engl. J. Med. 318(19), 1225–1230 (1988)PubMedCrossRef
27.
M.M. Byrne, J. Sturis, R.J. Sobel, K.S. Polonsky, Elevated plasma 2 h post challenge predicts defects in beta-cell function. Am. J. Physiol. 270(4 pt1), E572–E579 (1996)PubMed
28.
S. Seino, T. Shibasaki, K. Minami, Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J. Clin. Invest. 121(6), 2118–2125 (2011)PubMedCrossRef
29.
J.L. Leahy, Pathogenesis of Type 2 diabetes mellitus, in Contemporary Endocrinology: Type 2 Diabetes Mellitus : An Evidence-Based Approach to Practical Management, ed. by M.N. Feinglos, M.A. Bethel (Humana Press, Totowa, 2008), pp. 17–33
30.
A. Clark, Pancreatic Islet Pathology in Type 2 diabetes, in Pancreatic Beta Cell in Health and Disease, ed. by S. Seino, G.J. Bell (Springer, New York, 2008), pp. 381–398CrossRef
31.
A. Basu, M.G. Pedersen, C. Cobelli, Commentary. Prediabetes: evaluation of β-cell function. Diabetes 61(2), 270–271 (2012)PubMedCrossRef
32.
M.A. Abdul-Ghani, D. Tripathy, R.A. Defronzo, Contributions of β-Cell dysfunction and insulin resistance to the pathogenesis of Impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29(5), 1130–1139 (2006)PubMedCrossRef
33.
M.A. Abdul-Ghani, K. Williams, R. DeFronzo, M. Stern, What is the best predictor of future type 2 diabetes? Diabetes Care 30(6), 1544–1548 (2007)PubMedCrossRef
34.
M.A. Abdul-Ghani, T. Abdul-Ghani, N. Ali, R.A. DeFronzo, One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes. Diabetes Care 31(8), 1650–1655 (2008)PubMedCrossRef
35.
M.A. Abdul-Ghani, V. Lyssenko, T. Tuomi, R.A. DeFronzo, L. Groop, Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes :results from the Botnia Study. Diabetes Care 32(2), 281–286 (2009)PubMedCrossRef
36.
J.M. Haus, T.P.J. Solomon, C.M. Marchetti, J.M. Edmison, F. Gonzalez, J.P. Kirwan, Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance. J. Clin. Endocrinol. Metab. 95(1), 323–327 (2010)PubMedCrossRef
37.
E. Ferrannini, A. Gastaldelli, P. Iozzo, Pathophysiology of Prediabetes, in Prediabetes and Diabetes Prevention, ed. by M. Bergman (W.B. Saunders Company, Philadelphia, 2011), pp. 327–340
38.
R.G. Mirmira, Saturated free fatty acids: islet β cell “stress ER”. Endocrine 42(6), 1–2 (2012)PubMedCrossRef
39.
R. Weiss, S. Dufour, S.E. Taksali, W.V. Tamborlane, K.F. Petersen, R.C. Bonadonna, L. Boselli, G. Barbetta, K. Allen, F. Rife, M. savoye, J. Dziura, R. Sherwin, G.I. Shulman, S. Caprio, Prediabetes in obese youth: a syndrome of impaired glucose tolerance, severe insulin resistance, and altered myocellular and abdominal fat partitioning. Lancet 362, 951–957 (2003)PubMedCrossRef
40.
R.A. DeFronzo, From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58(4), 773–795 (2009)PubMedCrossRef
41.
A. Vella, Mechanism of action of DPP-4 inhibitors-new insights. J. Clin. Endocrinol. Metab. 97(8), 2626–2628 (2012)PubMedCrossRef
42.
E. Muscelli, A. Casolaro, A. Gastaldelli, a Mari, G. Seghieri, B. Astiarraga, Y. Chen, M. alba, J. Holst, E. Ferrannini, Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J. Clin. Endocrinol. 97(8), 2818–2819 (2012)CrossRef
43.
M. Bergman, Treatment of prediabetes. Louvain Med 131(3), 104–113 (2012)
44.
R.E. Ratner, A. Sathasivam, Treatment recommendations for prediabetes, in Prediabetes and Diabetes Prevention, ed. by M. Bergman (W.B. Saunders Company, Philadelphia PA., 2011), pp. 385–397
45.
J. Armato, R.A. DeFronzo, M. Abdul-Ghani, R. Ruby, Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction. Endocr. Pract. 18(3), 342–350 (2012)PubMedCrossRef
46.
V. Aroda, R. Ratner, Approach to the patient with prediabetes. J. Clin. Endcorinol. Metab. 93(9), 3259–3265 (2008)CrossRef
47.
A. Ramachandran, C. Snehalatha, Diabetes Prevention Programs, in Prediabetes and Diabetes Prevention, ed. by M. Bergman (W.B. Saunders Company, Philadelphia PA, 2011), pp. 353–372
48.
49.
W.A. Hsueh, L. Orloski, K. Wyne, Prediabetes: the importance of early identification and intervention. Postgrad. Med. 122(4), 129–142 (2010)PubMedCrossRef
50.
D.M. Nathan, M.B. Davidson, R.A. DeFronzo, R.J. Heine, R.R. Henry, R. Pratley, B. Zinman, Impaired fasting glucose and impaired glucose tolerance: implications for care consensus statement from American diabetes association. Diabetes Care 30, 753–759 (2007)PubMedCrossRef
51.
J.L. Chiasson, R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik, M. Laakso, STOP-NIDDM trial research group, Acarbose for prevention of type 2 diabetes: the STOP-NIDDM randomised trial. Lancet 359, 2072–2077 (2002)PubMedCrossRef
52.
R. Kawamori, N. Tajima, Y. Iwamoto, A. Kashiwagi, K. Shimamoto, K. Kaku, Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 1607–1614 (2009)
53.
R. Moriya, T. Shirakura, J. Ito, S. Mashiko, T. Seo, Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am. J. Physiol. Endocrinol. Metab. 297, E1358–E1364 (2009)PubMedCrossRef
54.
Effect of nateglinide on the incidence of diabetes and cardiovascular events, Navigator study group. N. Engl. J. Med. 362(16), 1463–1476 (2010)CrossRef
55.
The ORIGIN Trial Investigators, Basal Insulin and Cardiovascular and Other Outcomes in dysglycemia. N. Engl. J. Med. 367(4), 319–328 (2012)CrossRef
56.
J. Segura, L.M. Ruilope, Treatment of prehypertension in diabetes and metabolic synderome: what are the pros? Diabetes Care 32(11, suppl 2), S284–S289 (2009)
57.
L. Niskanen, T. Hedner, L. Hansson, J. Lanke, A. Niklason, For the CAPP study group. Diabetes Care 24(12), 2091–2096 (2001)PubMedCrossRef
58.
R. DeFronzo, M. Abdul-Ghani, Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol. 108(suppl), 3B–24B (2011)PubMedCrossRef
59.
E.N. Taylor, F.B. Hu, G.C. Curhan, Antihypertensive medications and the risk of incident type 2 diabetes. Diabetes Care 29(5), 1065–1070 (2006)PubMedCrossRef
60.
C. Manrique, M. Johnson, J.R. Sowers, Thiazide diuretics alone or with β-blockers impair glucose metabolism in hypertensive patients with abdominal obesity. Hypertension 55(1), 15–17 (2010)PubMedCrossRef
61.
W.J. Elliott, P.M. Meyer, Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369(9557), 201–207 (2007)PubMedCrossRef
62.
N. Sattar, D. Preiss, H.M. Murray, P. Welsh, B.M. Buckley, A.J.M. de Craen, S.R.K. Seshasai, J.J. McMurray, D.J. Freeman, J.W. Jukema, P.W. Macfarlane, C.J. Packard, D.J. Stott, R.G. Westendorp, J. Shepherd, B.R. Davis, S.L. Pressel, R. Marchioli, R.M. Marfisi, A.P. Maggioni, L. Tavazzi, G. Tognoni, J. Kjekhus, T.R. Perdersen, T.J. Cook, A.M. Gotto, M.B. Clearfield, J.R. Downs, H. Nakamura, Y. Ohashi, K. Mizuno, I. Ford, Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 375(9716), 735–742 (2010)PubMedCrossRef
63.
P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, R.J. Glynn, Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trail. Lancet 380(9841), 565–571 (2012)PubMedCrossRef
64.
A. Goldfine, Statins: is it really time to reassess benefits and risk? N. Engl. J. Med. 366(19), 1752–1755 (2012)PubMedCrossRef
Metadata
Title
Pathophysiology of prediabetes and treatment implications for the prevention of type 2 diabetes mellitus
Author
Michael Bergman
Publication date
01-06-2013
Publisher
Springer US
Published in
Endocrine / Issue 3/2013
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-012-9830-9

Other articles of this Issue 3/2013

Endocrine 3/2013 Go to the issue

Erratum

Erratum to: Spinal deformity index in patients with type 2 diabetes

Original Article

Spinal deformity index in patients with type 2 diabetes

Editorial

Type 2 diabetes and fractures: more information is needed

Original Article

Enhanced effect of zinc and calcium supplementation on bone status in growth hormone-deficient children treated with growth hormone: a pilot randomized controlled trial

Original Article

Association of Hashimoto’s thyroiditis with cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) and inducible co-stimulator (ICOS) genes in a Kuwaiti population

Original Article

Swim training of monosodium l-glutamate-obese mice improves the impaired insulin receptor tyrosine phosphorylation in pancreatic islets
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits